You are here

Award Data

For best search results, use the search terms first and then apply the filters

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Mitochondrial Antioxidant Neurodegenerative Therapeutics: XJB-5-131 Derivatives


    DESCRIPTION (provided by applicant): Oxidative damage to mitochondrial is a major source of toxicity in diseases such as Alzheimer's (AD), Parkinson's (PD), and Huntington's diseases (HD). Mitochondria are energy powerhouses of the cell, and decline in their function by oxidative damage is a common feature among neurodegenerative diseases. Despite years of effort, however, generic ...

    STTR Phase I 2014 Department of Health and Human Services
  2. The Allogeneic Heart Stem Cell Trial in Hypoplastic Left Heart Syndrome Patients

    SBC: CAPRICOR, INC.            Topic: NHLBI

    DESCRIPTION provided by applicant One of the most complex forms of congenital heart disease hypoplastic left heart syndrome HLHS affects an average of in every newborns with a mortality rate of up to percent during the first year of life The overall goal f our research is to develop safe and effective ways to improve short term and long term survival rates in babies born with HL ...

    STTR Phase I 2016 Department of Health and Human Services
  3. Antivirals Targeting Flavivirus Envelope Proteins

    SBC: L2 Diagnostics, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): The overall goal of this project is to develop therapeutic antivirals to treat life-threatening flavivirus infections. Enfuvirtide, a clinically successful peptide HIV fusion inhibitor, is the prototype for a new class of antivirals that inhibit viral envelope protein structural rearrangements essential for viral entry into host cells. In preliminary experiment ...

    STTR Phase I 2006 Department of Health and Human Services
  4. In toto Handheld Bioagent Detector by Digital Fluidics

    SBC: Core MicroSolutions, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): The design and evaluation of a handheld digital microfluidic (DMF) bioagent analyzer is proposed by Core Microsolutions (CMSS) and University of Michigan Professor K.-D. Lee (College of Pharmacy) for a two year Phase I research period in the NIH Small Business Biodefense Program. This proposed research will integrate: 1) Electrowetting on Dielectric (EWOD) drop ...

    STTR Phase I 2004 Department of Health and Human Services
  5. Whole Brain Nanoscale Preservation Imaging

    SBC: Nectome Inc.            Topic: 101

    Abstract Summary Nectome will create technologies to enable whole brain nanoscale preservation and imaging a vital step towards a deep understanding of the mind and of the brainandapos s diseases Current brain processing technologies compromise between whole brain applicability or nanoscale resolution our technologies will achieve both si multaneously Similar to the way that next generation ...

    STTR Phase I 2016 Department of Health and Human Services
  6. Safety of intraarticular N-acetylglucosamine

    SBC: ARTYX PHARMACEUTICALS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Osteoarthritis (OA) is the most prevalent joint disease, causing joint pain and dysfunction. OA is also associated with substantial co-morbidity and reduces life expectancy. Pharmacologic therapy is limited to symptom modification and disease-modifying therapies are currently not available. Furthermore, even symptom-modifying therapies are limited in efficacy a ...

    STTR Phase I 2006 Department of Health and Human Services
  7. Automated Parkinson's Disease Dopamine Transporter Scan Analysis Fast Track

    SBC: Molecular Neuroimaging, L.l.c.            Topic: N/A

    DESCRIPTION (provided by applicant): We hypothesize that for a class of dopamine transporter SPECT agents, an automated software processing package can be developed, which will objectively yield striatal quantitative uptake values for evaluating Parkinson' s disease (PD) diagnosis and progression. This fully automated and Objective Striatal Analysis (OSA) package will be able to evaluate subjects ...

    STTR Phase I 2007 Department of Health and Human Services
  8. Novel therapy for Fragile X syndrome

    SBC: Epigen Biosciences, Inc.            Topic: 101

    PROJECT SUMMARY Fragile X syndromeFXSis the most common inheritable form of cognitive impairment and the leading known genetic cause of autismFXS is caused by the loss of expression of the fragile X mental retardation proteinFMRPA major challenge for FXS research is to develop treatment strategies that improve the intellectual capabilities of patientsDysregulated protein synthesis is widely accept ...

    STTR Phase I 2017 Department of Health and Human Services
  9. Lipid/DNA/Antigen Complexes for Influenza A Viral Vaccination


    DESCRIPTION (provided by applicant): Influenza A (fluA) infection causes annual substantial morbidity and mortality worldwide, particularly for infants, the elderly, and the immuncompromised. FluA mainly replicates in the respiratory tract, with virulent strains also disseminating to other tissues, such as the central nervous system. A growing concern is the recent spread of virulent avian influen ...

    STTR Phase I 2006 Department of Health and Human Services
  10. Trigeminal Nerve Stimulation for Epilepsy

    SBC: NeuroSigma, Inc.            Topic: NINDS

    DESCRIPTION (provided by applicant): The purpose of this STTR project is to perform three key tasks essential to the ultimate FDA approval and commercialization of a new minimally invasive treatment for epilepsy, Trigeminal Nerve Stimulation. Epilepsyis a chronic condition characterized by recurrent seizures, and affects over three million Americans. One million (30 percent) have poorly contro ...

    STTR Phase I 2011 Department of Health and Human Services
US Flag An Official Website of the United States Government